MRS2 and familial pancreatic carcinoma: Positive clones from the first screening were applied to the second screening, in which clones producing antibodies that showed positive reaction to Hpt derived from a pancreatic cancer patient (PC-Hpt) and negative reaction to that derived from a healthy volunteer (HV-Hpt) were selected.